A Seattle Intensivist's One-pager on COVID-19

Nick Mark, MD
@nickmmark

Nomenclature

Infection: Coronavirus Disease 2019 a.k.a. COVID-19
Virus: SARS-CoV-2, 2019 Novel Coronavirus
NOT "Wuhan Virus"

Biology

- 30 kbp, +ssRNA, enveloped coronavirus
- Likely zoonotic infection; source/reservoir unclear (Bats? / Pangolins? → people)
- Now spread primarily ***person to person***;
    - Can be spread by asymptomatic carriers!
- Viral particles enter into lungs via ***droplets***
- Viral S spike binds to ACE2 on type two pneumocytes
- Effect of ACE/ARB is unclear; not recommended to change medications at this time.
- Other routes of infection (contact, enteric) possible but unclear if these are significant means of spread

Epidemiology

- Attack rate = 30-40%
- R_0 = 2-4
- Case fatality rate (CFR) = 3.4% (worldwide numbers)
- Incubation time = 4-14 days (up to 15 days)
- Viral shedding – median 20 days (max 37 days)

Timeline:

- China notifies WHO 2019-12-31
- First US case in Seattle 2020-1-15
- WHO Declared pandemic 2020-3-11
- National emergency 2020-3-12

Disease clusters: SNFs, Conferences, other
Strategies: contact tracing, screening, social distancing



v2.3.0 2020-03-15

Diagnosis/Presentation

Symptoms

- 65-80% **cough**
- 45% **febrile** on presentation (85% febrile during illness)
- 20-40% dyspnea
- 15% URI symptoms
- 10% GI symptoms

Labs

- CBC: Leukopenia & **lymphopenia** (80%+)
- BMP: ↑BUN/Cr
- LFTs: ↑AST/ALT/Tbili
- ↑ D-dimer, ↑ CRP, ↑ LDH
- ↑ IL-6, ↑ Ferritin
- ↓ Procalcitonin

  PCT may be high w/ superinfxn (rare)



Imaging

- CXR: hazy **bilateral**, **peripheral** opacities
- CT: **ground glass opacities** (GGO), crazy paving, consolidation, *rarely may be unilateral*



- POCUS: numerous B-lines, pleural line thickening, consolidations w/ air bronchograms

Isolation

- Phone call is the best isolation (e.g. move to telemed)
- Place patient in mask, single room, limit/restrict visitors

Precautions

- **In correct sequence**: **STANDARD** + **CONTACT** (double glove) + either **AIRBORNE** (for aerosolizing procedures: intubation, extubation, NIPPV, suctioning, etc) or **DROPLET** (for everything else)
- N95 masks must be fit tested; wear eye protection
- PPE should be donned/doffed with trained observer
- Hand hygiene: 20+ seconds w/ soap/water or alcohol containing hand gel

Treatment

- Isolate & send PCR test early (may take ***days*** to result)
- GOC discussion / triage
- Notify DOH, CDC, etc
- **Fluid sparing** resuscitation
- ± empiric antibiotics
- Intubate early under controlled conditions if possible
- Avoid HFNC or NIPPV (aerosolizes virus) unless ***individualized*** reasons exist (e.g. COPD, DNI status, etc); consider **helmet mask** interface (if available) if using NIPPV
- Mechanical ventilation for ARDS
    - **LPV** per ARDSnet protocol
    - 7 P's for good care of ARDS patients: e.g **PEEP**/**Paralytics**/**Proning**/inhaled **Prostacyclins**, etc
    - ? High PEEP ladder may be better
    - ? ECMO in select cases (unclear who)
- Consider using POCUS to monitor/evaluate lungs
- Investigational therapies:
    - Remdesivir --| block RNA dependent polymerase
    - Chloroquine --| blocks viral entry in endosome
    - Oseltamivir --| block neuraminidase
    - Lopinavir/ritonavir --| protease inhibitor
    - Tocilizumab --| block IL-6 (reduce inflammation)
    - Corticosteroids --| block T-cells (reduce inflammation)
- None of these investigational therapies is proven, but literature is evolving quickly.

Prognosis

- **Age** and **comorbidities** (**DM**, **COPD**, **CVD**) are significant predictors of poor clinical outcome; admission **SOFA** score also predicts mortality.
- Lab findings also predict mortality
    - ↑ d-dimer,
    - ↑ferritin
    - ↑ troponin
    - ↑ cardiac myoglobin
- Expect prolonged MV
- Watch for complications: Secondary infection (VAP), **Cardiomyopathy**